Skip to content
Screener

Capricor Therapeutics CAPR Q3 2025 earnings

Reported November 10, 2025 · After market close

Revenue-
EPS-$0.54In line
EPS estimate-$0.54

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$41.7M
EPS estimate-$0.14

Financials

Q3 2025

Income statement

See full
Revenue--100%
Operating income-$26.3M-102%
Net income-$24.6M-95.7%
EPS (diluted)-$0.54-42.1%

Balance sheet

See full
Cash & equivalents$19.5M-71.5%
Total debt$14.5M+189%
Total equity$83.9M+22.9%
Total assets$126.4M+36.0%

Cash flow

See full
Operating cash flow-$19.7M-69.1%
CapEx$55.8K+511%
Free cash flow-$19.7M-69.5%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$329.62M-38.7%
Enterprise value$324.65M-31.5%
P/S29.6×+6.5×

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-107.8%—
Debt / equity0.2×+0.1×
Current ratio3.6×-0.6×

FAQ

When did Capricor Therapeutics report Q3 2025 earnings?
Capricor Therapeutics (CAPR) reported Q3 2025 earnings on November 10, 2025 after market close.
What were Capricor Therapeutics's Q3 2025 revenue and EPS?
Capricor Therapeutics reported revenue of - and eps of $-0.54 for Q3 2025.
Did Capricor Therapeutics beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.54 by $0.00.
How did Capricor Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $2.3M a year earlier and eps declined 42.1% from $-0.38.
Where can I find Capricor Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-109119) and the 10-Q periodic report (0001104659-25-109298) directly on SEC EDGAR. The filing index links above go to sec.gov.